Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Our purpose is Making Access Happen by pioneering novel approaches to help people around the world access high-quality medicine and support the the UK's growing healthcare needs.
Our broad portfolio of high-quality medicines, covering all major therapeutic areas and increasingly focused on value-adding differentiated medicines, accounted for 2018 sales of USD 9.9 billion. Our work translates into substantial and ongoing savings for patients and payers, which help ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach more than 500 million patients and our aspiration is to reach one billion. Sandoz is committed to increasing patient access to high-quality biosimilars in the UK. We annually supply approximately 120 million packs of medicines to patients and the NHS. Our broad portfolio is spearheaded by our global leadership position in both biosimilars and generic antibiotics. We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals.